REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT02499822

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02499822
Other papers using this trial's data
  • A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension American journal of hypertension, 2025-03-17 DOI, PubMed 39657776

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Greece, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02499822. Randomized; single masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2020-07-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
Acronym
REVERENT
Condition
Hypertension
Condition
High Blood Pressure Variability
Intervention (Drug)
Nifedipine GITS
Intervention (Drug)
Ramipril
Lead sponsor
Istituto Auxologico Italiano (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02499822
Content hash
3c3abc25504778dcd2bada7c57850e6cddcbfced77dde17be21d8f2ce14c71ec